newsfilter
← Earnings
Earnings Releases·

Humacyte — Third Quarter 2026 Earnings Summary

  • Total revenue reached $1.028 million in Q3 2026, up 36% year-over-year and 157% sequentially, driven by Symvess product revenue of $1.023 million, while the net loss narrowed to $15.5 million from $17.5 million in the prior-year period.
  • Management raised Q4 2026 Symvess sales guidance to at least double Q3 levels ($1.0 million) based on expanded hospital adoptions, with plans to add at least 20 new hospitals in the second half of 2026.
  • Regulatory milestones include an SBLA filing for ATEV in dialysis access scheduled for November 2026 and the initiation of a Phase 2a CTEV study in November 2026 following FDA acceptance of the IND application.
  • The company recorded $9.119 million in insurance recovery assets and reduced contingent earnout and warrant liabilities, though it recognized a $9.75 million litigation settlement liability and $0.6 million in related legal expenses.
  • Board expansion included the appointment of Scott Coward and Paul Kuznik, while commercial momentum was supported by the addition of two new medical advisors for ATEV dialysis access commercialization.
Company
HUMACYTE INC
Sector
Healthcare
Industry
Biotechnology